PyngMedical.com » Awards

Pyng Medical is Honored for a Life & Limb Saving Tourniquet Design

admin — Mon, 13 Dec 2010 17:25:27 +0000

Vancouver, British Columbia – December 13, 2010 (PYT: TSX.V) Pyng Medical Corp. received the silver award from Industrial Designers Society of America for its Mechanical Advantage Tourniquet (MAT®). The award is part of IDSA’s Design of the Decade (DoD) competition and falls under the category of “Solution to a developing world social problem”.

“We are honored that the MAT® is acknowledged as a Design of the Decade.” commented Nadine Gaston, Vice President of Global Sales and Marketing for Pyng.

The MAT® is recognized for its speed and effectiveness, stopping blood loss in 10 seconds and is simple enough to apply one-handed.

The DoD panel awarded 12 golds, six silvers and two bronzes in 12 categories, which included, “Best sustainable design solution”, “Design’s contribution to business efficiency” and “Biggest contribution to brand growth”.

The designs were judged on their benefit to society, benefit to business and innovation, benefit to user and responsibility, and benefit to client and visual appeal.

"It clarifies the benefits of the MAT® Tourniquet’s superior design at a time when new tourniquet protocols are being implemented world-wide”, added Nadine Gaston, Vice President of Global Sales and Marketing.

The panel of judges included top design representatives from consultancies, companies and corporations, including: Chris Bangle, BMW’s former director of design; Marc Greuther, chief curator, The Henry Ford; and David Butler, IDSA, vice president of global design, The Coca-Cola Co.

The MAT® is a past winner of the IDSA’s Gold Award for Best Medical Product Design of 2006 and in 2007 a finalist for the INDEX Award for best medical product in the world.

About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

For more information contact:
Nadine Gaston
VP of Global Sales & Marketing
ngaston@pyng.com

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Pyng Medical Earns Top Honors From LifeSciences BC

josh.pratt — Mon, 17 Mar 2008 22:36:11 +0000

wp-image-113" height="61" src="http://www.pyng.com/wp/wp-content/uploads/2010/06/lsbc_logosmall.jpg" style="padding: 5px; margin-left: 5px;" title="LifeSciences BC
logo" width="216" />Vancouver, BC - Pyng Medical Corp. (PYT: TSX .V) today announced it has received the exclusive 2008 Medical Device Company of the Year Award from LifeSciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1™ Intraosseous Infusion System. FAST1™ is the most rapid, reliable and safe alternative to conventional IV infusion providing lifesaving vascular access for fluid and drug resuscitation in shock and trauma victims.

“LifeSciences BC is the premier association representing approximately 90 BC-based biotechnology and medical device companies comprising the 7th largest and fastest growing cluster in North America. As one of the most credible and influential industry organizations with government, academia, business and the investment community, it is a distinct honor for Pyng to receive independent validation as the 2008 Medical Device Company of the Year,” said David Christie, President and Chief Executive Officer. “I would like to acknowledge the collective contribution of the entire team at Pyng which is uniquely capable and committed to maintaining our market position as the world’s leading provider of life-saving sternal intraosseous infusion systems.”

“With five consecutive quarters of growth and profits, Pyng has made substantive progress increasing revenues from product sales while executing on an expanded business strategy aimed at facilitating adoption in new large domestic and international market opportunities including the hospital environment,” adds Christie.

As part of its on-going commitment to technology innovation, the Company is developing next generation intraosseous products and aggressively exploring acquisition and in-licensing opportunities to broaden its product portfolio with complimentary technologies. Pyng recently received US FDA market clearance and commercially launched a new and improved FAST1 system with a re-engineered infusion tube that no longer requires the use of a removal tool. Pyng also continues to expand its patent portfolio and has applied for trademark protection on Chest is Best™, reinforcing the benefits of rapid infusion through their unique FAST1 sternal line.

About LifeSciences British Columbia (formerly BC Biotech)

LifeSciences British Columbia supports and represents the biotechnology, medical device and greater life sciences community of British Columbia through leadership, advocacy and promotion of our world-class science and industry. Via active facilitation of partnering and investment into the life sciences sector, British Columbia is fast becoming a global life sciences leader. LifeSciences British Columbia is a not-for-profit, non-government, industry-funded association.

About Pyng Medical Corp.

Pyng Medical Corporation is the developer and manufacturer of the proprietary, award-winning FAST1™ Intraosseous Infusion System. Pyng was selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1™ has worldwide application for use with hospitals, emergency medical services and military forces.

For More Information

George Dorin
Pyng Medical Corp.
(604) 303-7964
www.pyng.com

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Pyng Medical Nominated for Richmond Business Excellence Award

sburnett — Wed, 02 Jan 2008 23:04:39 +0000

Pyng Medical Corp. was nominated for a Business Excellence Award through the Richmond Chamber of Commerce.

Pyng Medical Corp. Achieves Top 10 Ranking in “2007 TSX Venture 50”

sburnett — Wed, 20 Jun 2007 23:43:58 +0000

Vancouver, BC – Pyng Medical Corp. has been selected as one of the “2007 TSX Venture 50″, a ranking of the top 10 Canadian public venture capital companies in 5 industry sectors listed on TSX Venture Exchange. The 10 finalists chosen in each industry sector— life sciences, mining, oil & gas, technology and diversified industries—were selected by a New York-based market research firm based on revenue, return on investment, trading volume and market capitalization growth for the year ending December 31, 2006.

“We are very proud to be recognized for this award from a field of 629 qualifying companies. These are very exciting times for those involved with Pyng Medical Corp.,” said David Christie, President and Chief Executive Officer. “This recognition confirms the growing awareness and demand for the FAST1™ Intraosseous Infusion System and reaffirms that we are moving into the mainstream with this innovative, life saving device”.

Pyng Medical revenue for fiscal 2006 was $3 million which was an increase of 55% over a two year period from 2004. The company also reported net profits for fiscal 2006 and 2005 resulting in a positive cash flow with no debts outstanding. Complete financial reports are available on www.sedar.com.

Full details of the 2007 TSX Venture 50 has been issued in The Globe and Mail, News Network and is also available at www.globeandmail.com.

About Pyng Medical Corp.

Pyng Medical Corp. is a world-leader in intraosseous infusion with its proprietary award-winning FAST1™ Intraosseous Infusion System. The FAST1™ is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.

For More Information

George Dorin
Pyng Medical Corp.
(604) 303-7964
www.pyng.com

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

MAT™ Selected as a Finalist for the Prestigious, International 2007 INDEX Award

sburnett — Wed, 28 Feb 2007 23:48:05 +0000

The INDEX: AWARD 2007 not only presents the very best in international design; all top nominated designs are also characterized by their ability to substantially improve people’s lives.

The top nominated designs were selected by a jury of venerable, international design experts including the Museum of Modern Art, the World Economic Forum, IDEO and Hong Kong Polytechnic University.

Continuing, independent military medical tests are reporting MAT™ providing unsurpassed performance and user preference above all other military and civilian tourniquets.

View INDEX Award top nominees

MAT™ receives 2006 IDSA Gold IDEA Award for Medical Product Design

sburnett — Mon, 07 Aug 2006 00:00:25 +0000

From a field of over 1490 international entries, MAT™ has been chosen as the recipient of the 2006 Gold IDEA Award for Medical Product Design.

IDEA 2006 Jurors express their thoughts about MAT™:

“The most important question to be asked of any design is ‘Does the world need this thing?’ With this tourniquet, the answer is an obvious ‘yes.’ It looks and feels as if it was designed in the field, not just for it.”
- John Thackara, Director, Doors of Perception

“…brings simplicity and elegance to a very traumatic event. Very appropriate aesthetics give a soft and comforting feeling without losing the perception that this is a serious piece of equipment.”
- Tor Alden, IDSA, Principal, HS Design Inc.

As featured in Business Week, July 10, 2006 issue

Pyng Honoured with 2000 Medical Design Excellence Award

sburnett — Fri, 30 Jun 2000 22:42:11 +0000

Pyng Medical Corp has been honoured with a Gold 2000 Medical Design Excellence Award for its FAST1™ Intraosseous Infusion System. Recognized in the Critical-Care and Emergency Medicine Products category, FAST1™ was singled-out for its ease-of-use, effectiveness, and rapid sternal delivery of critical fluids and medications to patients for whom IV is difficult or impossible. | Article